Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study
Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Listed as NCT00169247, this PHASE2 trial focuses on Hypopharynx Cancer and Larynx Cancer and remains completed. Sponsored by Groupe Oncologie Radiotherapie Tete et Cou, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Groupe Oncologie Radiotherapie Tete et Cou
- Tumor Study Group Head and Neck
For direct contact, visit the study record on ClinicalTrials.gov .